GC
VYGR icon

Guggenheim Capital’s Voyager Therapeutics VYGR Stock Holding History

Guggenheim Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,401
Closed -$228K – 1961
2023
Q3 		$228K Buy
+29,401
New +$268K ﹤0.01% 1722

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Guggenheim Capital's VYGR Position: Q4 2023 in Review

Guggenheim Capital sold out of Voyager Therapeutics (VYGR) in Q4 2023, closing a stake of 29,401 shares — an estimated $228K sold.

Guggenheim Capital first reported a position in VYGR in Q3 2023 and held it in 1 quarter. The position peaked at $228K in Q3 2023. 107 funds tracked by Wall St. Rank hold VYGR as of Q4 2023.

  • Guggenheim Capital reported no remaining Voyager Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Guggenheim Capital sold 29,401 Voyager Therapeutics shares in Q4 2023, an estimated $228K.
  • Guggenheim Capital first reported a position in Voyager Therapeutics in Q3 2023 and held it in 1 quarter.
  • Guggenheim Capital's Voyager Therapeutics position peaked at $228K in Q3 2023.
  • 107 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2023.

Based on Guggenheim Capital's 13F filing for Q4 2023, filed 14 Feb 2024.